论文部分内容阅读
目的探讨超敏C反应蛋白(hs-CRP)在肺尘埃沉着病(尘肺)合并肺部感染疗效评估方面的价值。方法 100例尘肺未合并肺部感染的患者作为对照组,150例尘肺合并肺部感染的患者作为观察组,比较观察组治疗前、后以及对照组血清hs-CRP水平。结果观察组治疗前hs-CRP浓度为(20.398±26.817)mg/L,对照组为(4.597±10.611)mg/L,观察组治疗前高于对照组(P<0.01)。观察组hs-CRP浓度治疗前为(20.398±26.817)mg/L,治疗后为(3.051±4.649)mg/L,治疗后低于治疗前(P<0.01)。结论 hs-CRP可作为尘肺合并肺部感染疗效评估的敏感指标。
Objective To investigate the value of hs-CRP in assessing the efficacy of pulmonary infection in pneumoconiosis (pneumoconiosis). Methods 100 patients with pneumoconiosis without pneumoconiosis were selected as the control group. 150 patients with pneumoconiosis and pulmonary infection were selected as the observation group. The serum hs-CRP levels in the observation group before and after treatment and in the control group were compared. Results The concentration of hs-CRP in the observation group before treatment was (20.398 ± 26.817) mg / L and in the control group (4.597 ± 10.611) mg / L, and the observation group was higher than the control group before treatment (P <0.01). The hs-CRP concentration in the observation group before treatment was (20.398 ± 26.817) mg / L, after treatment (3.051 ± 4.649) mg / L, after treatment was lower than before treatment (P <0.01). Conclusion hs-CRP can be used as a sensitive indicator of the efficacy of pneumoconiosis and pulmonary infection.